Please assess the completion status of the following clinical trial:

Trial Title: A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and postmenopausal women aged ≥50 who have sustained a unilateral, fracture of the trochanteric region~* Lumbar spine BMD and/or femoral neck BMD and/or total hip BMD measurement of the contra lateral hip at least 2.0 SDs (standard deviation) below the average bone mass for young women and men~Exclusion Criteria:~* Clinically significant abnormal laboratory values~* History of unresolved skeletal diseases that affect bone metabolism~* Polytrauma participants and participants with fractures at more than one site

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teriparatide (Type: EXPERIMENTAL): 20 micrograms (mcg) a day by subcutaneous injection throughout study.~Placebo oral tablets once a week, to match the active comparator weekly dose, during the double-blind, double-dummy phase only.
- Risedronate (Type: ACTIVE_COMPARATOR): 35 milligrams (mg) risedronate sodium orally once weekly throughout study.~Daily placebo injection, to match the daily experimental drug dose, during the double-blind, double-dummy phase only.

Based on this trial design, predict the completion outcome and termination type (if applicable).